KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53.

Saved in:
Bibliographic Details
Title: KMT2D depletion promotes KRAS-induced pancreatic carcinogenesis independent of TP53.
Authors: Tolosa EJ; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Raja Arul GL; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA; Molecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA., Sigafoos AN; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Ferrero V; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Pease DR; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Almada LL; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Vera RE; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Pena Ruiz NM; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA; Molecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA., Hogenson TL; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., LaRue-Nolan KC; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA; Molecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA., Tader BR; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Graham RP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Brown M; Division of Endocrinology, Metabolism, Diabetes, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA., Hagen CE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Matveyenko AV; Division of Endocrinology, Metabolism, Diabetes, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA., Carr RM; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Ge K; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA., Fernandez-Zapico ME; Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: FernandezZapico.Martin@mayo.edu.
Source: The Journal of biological chemistry [J Biol Chem] 2026 May 27; Vol. 302 (7), pp. 113203. Date of Electronic Publication: 2026 May 27.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1083-351X
DOI:10.1016/j.jbc.2026.113203